Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC), Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05585034
Phase: Phase 1
Trial Summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Xencor, Inc.
Acronym:

Pin It on Pinterest